This variation reflects the different levels of the STING pathway under various microenvironmental states.228 Such differential expression levels could be one of the reasons why latent metastatic cancers and advanced metastatic cancers have distinct responses to STING agonists. This evidence concerns the gene STING1 and metastatic malignant neoplasm.